Pfizer’s BRAFTOVI combo shows breakthrough results in aggressive colorectal cancer
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
Subscribe To Our Newsletter & Stay Updated